Harbour BioMed
Shanghai, China harbourbiomed.com From their website, Nov 2026
Work here? Claim this listing
About
Harbour BioMed is a biopharmaceutical company focused on discovering and developing novel antibody therapeutics. It serves global partners from R&D centers in China, the United States, and Europe, with work spanning antibody discovery platforms, clinical development, and strategic collaborations.
Services
Harbour Mice® antibody technology platform
Generates fully human monoclonal antibodies in H2L2 and heavy chain-only (HCAb) formats.
Single Cell Technology Platform
Provides a full single B cell cloning process including enrichment, separation, screening, sequencing, recombinant antibody production, and verification.
HBICE® bispecific antibody technology
Uses HCAb-based immune cell engagers to generate flexible bispecific formats for different mechanisms of action.
HCAb PLUS™ technology
Provides modality solutions for developing innovative multi-specific medicines across disease areas.
Generative AI HCAb Model
Uses the Hu-mAtrIx™ AI platform to support fully human HCAb model development and accelerate therapy generation.
Clinical Development & Medical Services
Delivers integrated clinical development from first-in-human studies through pivotal registration studies and post-marketing studies.
Co-development
Shares design, execution, and risk of clinical trials with global partners.
Technology Service
Provides technology support through fee-for-service and FTE arrangements.
3 more services
- Technology License
- Asset License
- Strategic Collaboration
Capabilities
- Assays and studies
- Antibodies
- Rodent models
- Bispecifics
- Small molecules
- NGS
- Single B cell cloning
6 more
- Single B cell separation
- Antibody binding screening
- Functional in-chip screening
- Single-cell antibody sequencing
- High-throughput recombinant antibody production
- Antibody verification
- Scale and capacity
- 150+ partners
- 400+ projects
- 20+ IND/clinical stage
- 140+ partners
- 380+ projects
- Over 100 senior scientists
- Therapeutic areas
- Immunology
- Oncology
- Immuno-oncology
- Weight management
Instruments and platforms
- Optofluidic technology
- Next-generation sequencing
Modalities and species
- Modalities
- Small molecule
- Antibody
- Bispecific
- ADC
- Species and models
- Murine CD138+ plasma cell
- Single B cell
- Mammalian display libraries
- Yeast display libraries
- Phage display libraries
Details
- Founded
- 2016
- Team
- Over 100 scientists
- Based in
- Shanghai, China
- Sites
- Beijing, China
- Suzhou, China
- Hong Kong, China
- Natick, MA, United States of America
- Rotterdam, Netherlands
- Serves
- Global, China, United States, Europe
Public records
- Parent company
- Harbour BioMed Therapeutics Limited · KY GLEIF